07/31/2017 04:17:00 pm
Afanasyev B. V. (St. Petersburg, Russia)
Wagemaker G. (Rotterdam, Netherlands)
Zander A.R. (Hamburg, Germany)
Fehse B. (Hamburg, Germany)
Chukhlovin A. B. (St. Petersburg, Russia)
Aleynikova O. V. (Minsk, Belarus)
Borset M. (Trondheim, Norway)
Chechetkin A. V. (St. Petersburg, Russia)
Fibbe W. (Leiden, Netherlands)
Galibin O. V. (St. Petersburg, Russia)
Hölzer D. (Frankfurt a.M., Germany)
Klimko N. N. (St. Petersburg, Russia)
Kolb H.-J. (München, Germany)
Kröger N. (Hamburg, Germany)
Kulagin A. D. (St. Petersburg, Russia)
Lange C. (Hamburg, Germany)
Mamaev N. N. (St. Petersburg, Russia)
Mikhailova N. B. (St. Petersburg, Russia)
Moiseev I. S. (St. Petersburg, Russia)
Nagler A. (Tel-Aviv, Israel)
Nemkov A. S. (St. Petersburg, Russia)
Paramonov I. V. (Kirov, Russia)
Roumiantsev A. G. (Moscow, Russia)
Savchenko V. G. (Moscow, Russia)
Smirnov A. V. (St. Petersburg, Russia)
Uss A. L. (Minsk, Belarus)
Zubarovskaya L. S., (St. Petersburg, Russia)
Under clinical studies, a group of pediatric oncologists (Yulia V. Skvortsova et al.) from D. Rogachev Memorial Center of Pediatric Hematology, Oncology and Immunology (Mos- cow) present a large review with sufficient clinical data on posttransplant lymphoproliferative disease (PTLD) which may develop after solid organ transplantations and alloge- neic hematopoietic stem cell transplantations (allo-HSCT), being a specific posttransplant complication in immuno- suppressed patients. Its origin is, most probably, viral (Ep- stein-Barr virus), but cytostatic treatment depends on its clinical and morphological features. The authors describe PTLD in a skilled manner, being both comprehensive and valuable to clinicians.
Another clinical article by Julia Yu. Vlasova et al. (St. Peters- burg-Moscow) deals with a special genetic variant of chronic myeloid leukemia (CML) which, due to T315I mutation in BCR/ABL gene, does not respond to the best available tar- geted treatment, i.e., Imatinib and some other tyrosine ki- nase inhibitors which are effective in majority of CML cases without such a mutation. The authors describe strategies of treatment for such cases including Ponatinib treatment, or allo-HSCT which can be a potential option for selected pa- tients.
A review by A. B. Chukhlovin describes some genes which may predispose for common immune complications in allo-HSCT, in order to demonstrate that a number of non- HLA genes may influence immune complications (e.g., acute GvHD) and total survival of the patients following allogeneic HSCT. Interestingly, many of these gene variants are encod- ed by donor genome, thus showing some value for genotyp- ing of HSCT donors to predict risk of immune disorders post-HSCT.
We could not also miss such an important event as a joint meeting of leading hematologists from M.D.Anderson Med- ical Center (Houston, Texas, USA) and Russian hemato-on- cologists devoted to diagnostics and treatment of myelo- and lymphoproliferative disorders. Emerging issues of molecular diagnostics and clinical trials of novel targeted drugs were presented and discussed.
Continuing discussion about novel legislation and regu- lations in the field of gene editing and its possible clinical introduction, we publish a short opinion on the matter by Mikhail Samsonov, a Moscow expert in R&D of novel medi- cal drugs. We would be glad to get alternative views concern- ing gene editing, gene therapy and, especially, new approach- es to cellular therapy in oncology.
Julia Yu. Vlasova1, Elena V. Morozova1, Oleg A. Shukhov2, Maria V. Barabanshchikova1, Tatiana L. Gindina1,
Ildar M. Barhatov1, Irina S. Martynkevich3, Vasily A. Shuvaev3, Anna G. Turkina2, Boris V. Afanasyev1
Irina P. Shipitsina1, Elena I. Gutovskaya1, Dina D. Bajdildina1, Irina I. Kalinina1, Ulyana N. Petrova1, Andrej B. Abrosimov1,
Svetlana N. Kozlovskaya1, Michael A. Maschan1, Dmitrij M. Konovalov1, Dmitrij S. Abramov1, Galina V. Tereshenko1,
Alexander G. Rumyantsev1, Elena V. Samochatova1, Galina A. Novichkova1, Alexej A. Maschan1